|
KMID : 0368820220610020133
|
|
Journal of the Korean Neuropsychiatr Association
2022 Volume.61 No. 2 p.133 ~ p.142
|
|
|
Korean Medication Algorithm Project for Bipolar Disorder 2022: Mixed Features
|
|
Kim Won
Bahk Won-Myong
Woo Young-Sup
Jeong Jong-Hyun
Seo Jeong-Seok
Choo Il-Han
Yang Chan-Mo
Lee Jung-Goo
Shim Se-Hoon
Yoon Bo-Hyun
Park Sung-Yong
Sohn In-Ki
Kim Moon-Doo
Jung Myung-Hun
Jon Duk-In
|
|
|
Abstract
|
|
|
Objectives Treatment guidelines or an algorithm can help clinicians implement better practices and clinical decisions. Therefore, the Korean Medication Algorithm Project for Bipolar Disorder 2022 (KMAP-BP 2022) was revised again through a consensus of expert opinion. The diagnosis and treatment of mixed features are not simple, and there are many things to discuss. We describe the preferences and recommendations from KMAP-BP 2022 for the treatment of mood episodes with mixed features.
Methods We revised the KMAP-BP 2018 questionnaire and conducted the survey with expert clinicians. Out of ninety-three members of the review committee, eighty-seven completed the survey. We analyzed the answers, discussed the data, and held a clinician hearing.
Results In first-step strategies for mixed features with more manic symptoms, a combination of a mood stabilizer and an atypical antipsychotic is the treatment of choice. Mood stabilizer monotherapy and atypical antipsychotic monotherapy are preferred strategies. For mixed features with more depressive symptoms, a combination of mood stabilizer and atypical antipsychotic, a combination of atypical antipsychotic and lamotrigine (LMT), atypical antipsychotic monotherapy, a combination of mood stabilizer and LMT, and mood stabilizer monotherapy are preferred. For mixed features with similar manic symptoms and depressive symptoms, a combination of mood stabilizer and atypical antipsychotic, atypical antipsychotic monotherapy, and mood stabilizer monotherapy are preferred.
Conclusion For mixed features, a combination of mood stabilizer and atypical antipsychotic is generally preferred, and LMT is preferred for depressive symptoms. Compared with KMAP-BP 2018, more diverse strategies and drugs are being attempted for the treatment of mixed features.
|
|
|
KEYWORD
|
|
|
Bipolar disorder, KMAP-BP 2022, Pharmacotherapy, Mixed features
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|